“Soframycin” Maker Encube Ethicals 3000 Crore IPO Is Pure Offer-For-Sale: Why Is Every Rupee Leaving India While The Promoter Buys 106 Crore Juhu Flat?

Encube Ethicals Limited has filed a Draft Red Herring Prospectus for an initial public offering of up to ₹3,000 crore. The number is large enough to attract retail attention. The structure behind the number, however, is simple and absolute, where the entire issue is an Offer for Sale. There is no fresh issue component. The company itself will receive zero proceeds from the listing.

Encube Ethicals 3000 crore IPO- entire component is ‘Offer-for-sale’.

According to the DRHP of Encube Ethicals, the offer comprises shares aggregating up to ₹2,000 crore from promoter Mehul Madhusudan Shah and up to ₹1,000 crore from Frontier Investment Holdings Pte. Ltd., a Singapore-based entity backed by private equity firm Quadria Capital. The company’s own language is unambiguous: “Fresh Issue Size: Not applicable.” The consequence is equally clear. Every rupee paid by investors in the IPO will flow to the two selling shareholders after expenses and taxes. None of it will strengthen the company’s balance sheet, fund capacity expansion, repay debt, or support research and development inside India.

This pure-exit design sits alongside another set of facts disclosed in the same document. In Fiscal 2026, Encube reported revenue from operations of ₹18,487 million. Of that total, revenue generated outside India stood at approximately 74 percent. The United States alone accounted for roughly 64.7 percent. India contributed about 24 percent. The geographical concentration has been rising: the US share moved from around 58–59 percent in earlier years to 64.7 percent in the latest fiscal. The company’s manufacturing base remains in India, primarily the Goa facility, which contributed 85.12 percent of Fiscal 2026 revenue, and a second site in Indore. Products are made in India; the majority of sales, and therefore the majority of cash flows, are realised abroad.

The combination creates a particular set of exposures for any Indian retail investor considering participation. An export-oriented pharmaceutical business whose largest market is the United States benefits when the rupee weakens against the dollar: dollar revenues translate into more rupees. The same business faces higher rupee costs for any imported raw materials, packaging, capital equipment, or specialised inputs priced in foreign currency. Depreciation of the Indian rupee therefore cuts both ways. The DRHP itself flags tariff risk, foreign-exchange volatility, and regulatory risk in overseas markets as material concerns. What the document does not do is inject fresh capital into the Indian operations that must absorb those costs.

The timing of a separate transaction adds another layer of public-interest questions. Property registration records show that Mehul Madhusudan Shah and Niti Shah acquired a luxury sea-facing apartment in Lodha Avalon, Juhu, for approximately ₹106.52 crore. The transaction was registered on or around 31 July 2026. Encube’s DRHP was filed days later. The apartment measures roughly 9,863 square feet of carpet area and includes multiple car parks. The purchase price works out to more than ₹1 lakh per square foot. The same promoter whose shares carry a weighted average cost of acquisition of ₹0.08 is simultaneously monetising a large block of those shares through the IPO and acquiring one of Mumbai’s more expensive residential properties.

The DRHP also discloses that the promoter and promoter group held 80.63 percent of the equity before the offer. A large nil-cost bonus allotment occurred in the weeks preceding the filing. The mechanical effect of a low historical cost base combined with a pure Offer for Sale is that the promoter realises a substantial multiple on shares that required little incremental cash investment, while the company itself receives nothing.

Concentration risks compound the picture. The top ten customers accounted for 59.74 percent of Fiscal 2026 revenue. A single facility in Goa generated more than 85 percent of sales. Three separate single points of failure, namely geography, customer base, and manufacturing site, sit inside a business that is asking public markets for a valuation while returning no capital to the enterprise.

Financial performance itself has been strong. Revenue rose from ₹10,859 million in Fiscal 2024 to ₹13,448 million in Fiscal 2025 and ₹18,487 million in Fiscal 2026. Restated profit for the year moved from ₹1,561 million to ₹2,496 million to ₹4,367 million over the same period. Operating cash flow has been positive. The growth numbers are real. The question that follows is structural rather than operational: if the business is generating substantial cash and expanding at this pace, why does the listing structure channel the entire public subscription to existing shareholders rather than to the company that is being valued?

From a public-interest perspective, several questions arise in sequence.

First, when an Indian-listed company raises capital that never enters its accounts and a material portion of the selling shareholder is a foreign investment vehicle, what is the net effect on domestic capital formation? The rupees paid by Indian retail and institutional investors leave the company’s balance sheet and, in the case of the Singapore entity, ultimately leave the Indian financial system.

Second, how should a retail investor weigh an export-heavy revenue base against a pure-exit IPO at a moment when the Indian rupee has experienced multi-year depreciation against the US dollar? Currency movement that boosts reported rupee revenues also raises the rupee cost of any imported inputs. Without fresh capital to buffer working-capital or capital-expenditure needs, the company remains dependent on internal accruals and future debt or equity raises.

Third, what signal does the near-simultaneous purchase of a ₹106 crore personal residence by the primary selling shareholder send about the intended use of IPO proceeds? The proceeds belong to the selling shareholders by design. The public observation is simply that the largest individual beneficiary of the Offer for Sale has chosen to deploy significant personal liquidity into an ultra-luxury residential asset in the same window in which the company is seeking a public listing.

Fourth, given that the Goa facility alone accounts for more than 85 percent of revenue and that the United States accounts for nearly two-thirds of sales, how resilient is the equity story to a single regulatory action at the manufacturing site or a shift in US trade or healthcare policy? The DRHP lists these risks. The pure OFS structure provides no additional capital cushion against them.

Fifth, the weighted average cost of acquisition figures, which is ₹0.08 for the promoter and ₹199.31 for the investor selling shareholder, create a wide gap between the historical cost of the shares being sold and the price at which retail investors will be asked to buy them. The gap is a mathematical outcome of historical capital structure and the recent bonus issue. The public question is whether that gap is adequately compensated by the growth trajectory and whether the absence of any primary capital raises the risk that future dilution will be required on less favourable terms.

None of these points constitute a judgment on the quality of Encube’s manufacturing capabilities, its USFDA track record relative to peers, or the legitimacy of a promoter exit after building a business over nearly three decades. They are structural observations drawn directly from the Encube Ethicals’s DRHP and from contemporaneous property records.

For the retail investor the practical sequence of questions is therefore narrow and factual. Does the absence of any fresh capital change the risk-reward calculation relative to a conventional IPO that funds growth? Does the heavy reliance on a single overseas market and a single domestic manufacturing site require a higher margin of safety in valuation?

Does the timing of a nine-figure personal real-estate acquisition by the primary selling shareholder affect the perception of alignment between promoter liquidity events and the company’s long-term capital needs? And, in an environment of ongoing rupee volatility, does an export-oriented cost structure without an accompanying capital infusion from the public issue introduce an additional layer of exposure that the DRHP itself acknowledges but does not capitalise against?

The document answers the first question with clarity: the company will receive nothing. The remaining questions are left for each investor to weigh against the growth numbers, the concentration metrics, the currency backdrop, and the personal capital allocation decisions visible in the public record. The data are disclosed. The connections between pure OFS, foreign revenue concentration, rupee dynamics, and promoter liquidity timing are observable. The public-interest task is simply to place those facts side by side and ask what they imply for the capital that retail investors are being invited to commit.

The pure OFS (Offer-for-sale) component is inherently not a red flag. That’s not automatically a warning sign, as many solid, well-funded companies go public entirely through an Offer for Sale simply because they don’t need new capital, and existing shareholders are looking to cash out. But it does shift what a retail investor should actually be asking. Rather than “what will the company do with this money,” the real question for anyone applying to the Encube Ethicals IPO becomes: “why are these particular shareholders exiting now, and at what valuation relative to how fast the company is actually growing?”

Disclaimer: This is not an investment advice. Investors are asked to consult their Financial Advisors before making any decision.